Publications

Below are some examples of publications by America'sHealth team members.

Hoffman A, Montgomery R, Aubry WM, Tunis SR. How Best to Engage Patients, Doctors, and Other Stakeholders in Designing Comparative Effectiveness Studies. Health Affairs, Vol. 29, No. 10: 1834-1841. October 2010.

Coffman JM, Hong MK, Aubry WM, Luft HS, Yelin EH. Translating Medical Effectiveness Research into Policy: Lessons from the California Health Benefits Review Program. Milbank Quarterly, Vol. 87, No. 4: 863-902. December 2009.

Rettig RA, Jacobson PD, Farquhar CM, Aubry WM. False Hope: Bone Marrow Transplantation for Breast Cancer. New York, Oxford University Press. January 2007.

Laugesen MJ, Paul RR, Luft HS, Aubry WM, Ganiats TG. A Comparative Analysis of Mandated Benefits Laws, 1949-2002. HSR, Vol. 41, No. 3 (Part II): 1081-1103. June 2006.

Luft HS, Rappaport KM, Yelin EH, Aubry WM. Evaluating Medical Effectiveness for the California Health Benefits Review Program. HSR, Vol. 41, No. 3 (Part II): 1007-1026. June 2006.

Aubry WM, Unger WJ. Prevalence of Implantable Cardioverter Defibrillator (ICD) Implants in the USA. ACVP CP Digest, Vol. 48, No. 4. December 2005.

Aubry WM. Reimbursement and Coverage Implications for CGM (Continuous Glucose Monitoring). Diabetes Technology & Therapeutics, Volume 7, No. 5: 797-800. October 2005.

Chuang KH, Aubry WM, Dudley RA. Independent Medical Review of Health Plan Coverage Denials: Early Trends. Health Affairs, Vol. 23, No. 6: 163-169. November/December 2004.

Collins S, Piper K, Owens G.  Making the Patient-Centered Medical Home (PCMH) and Reduced Costs a Reality.  American Journal of Managed Care. In-press. 

Collins S, Collins W.  Innovative Biotechnology Industry Strategies in the U.S.’ Rapidly Evolving Payer Environment.  Journal of Commercial Biotechnology.  In-press. 

Collins S, Collins W. Innovative Biotechnology Industry Strategies in the U.S.' Rapidly Evolving Payer Environment. Journal of Commercial Biotechnology. In-press. June 2012.

Collins S. Primary Care Shortages: Strengthening This Sector Is Urgently Needed, Now and in Preparation for Healthcare Reform. American Health and Drug Benefits, Vol. 5, No. 1: 40-47. January/February 2012.

Collins S. The Growing Importance of Incorporating US Payers into Biotechnology Drug Development Decision-Making. Journal of Commercial Biotechnology, Vol. 17:151-158. May 2011.

Collins S. Why Manufacturers Should Listen to Employer Concerns Now. Biotechnology Healthcare. [Special report, hard copy only.] Spring 2011.

Collins S. Many Federal CER Projects Will Benefit Managed Care. Managed Care. February 2011.

Collins S. Specialty Pharmacy Management Will Become More Intense. Managed Care. October 2010.

Collins S. Oncology Biomarker Diagnostics: Where We Are, Where We Need to Be. Biotechnology Healthcare, Vol. 7, No. 3: 22-25. Fall 2010.

Collins S. Performance-Based Contracting Can Align Stakeholder Interests. Specialty Pharmacy News. August 2009.

Piper KB. The New Accountable Care Organizations and Medicare Gain-Sharing Program. American Health and Drug Benefits, Vol. 3, No. 4: 261-262. July/August 2010.

Piper KB. Accountable Care Organizations in the Era of Healthcare Reform: Interview with Mark B. McClellan, MD, PhD. American Health and Drug Benefits, Vol. 3, No. 4: 242-244. July/August 2010.

Piper KB. The Health Reform Law: Key Changes to Be Implemented in 2010. American Health and Drug Benefits, Vol. 3, No. 3: 180-181. May/June 2010.

Piper KB. Federal Drug Price Controls in Medicaid: Expansion of Mandated Rebates under Health Reform Law. American Health and Drug Benefits, Vol. 3, No. 3: 182-184. May/June 2010.

Piper KB. Wellness-Based Healthcare Policy: Medicare, Medicaid, and Private Insurance. American Health and Drug Benefits, Vol. 3, No. 2, Supp. 6: S104-S108. March/April 2010.

Heit M, Piper KB. Global Payments to Improve Quality and Efficiency in Medicaid. Massachusetts Medicaid Policy Institute. November 2009.

Piper KB. Healthcare Reform and Public Programs: Opportunities for TIA/Recurrent Stroke Prevention. American Health and Drug Benefits, Vol. 2, No. 6, Supp. 8: S28-S32. September/October 2009.

Piper KB. New Government Policies: Opportunities for Supporting Research and Development. American Health and Drug Benefits, Vol. 2, No. 4, Supp. 6: S161-S163. June/July 2009.